Carolina Molecular and Astoriom launch partnership for integrated testing and biospecimen storage
Carolina Molecular and Astoriom have formed a strategic partnership to deliver combined molecular testing and biospecimen storage services for life sciences customers.
The two Research Triangle Park-based companies said the collaboration is designed to streamline workflows for pharmaceutical and biotechnology partners, as well as CROs and CDMOs, by linking molecular testing capabilities with regulated sample storage. The offering is intended to improve efficiency from sample receipt through to advanced analysis, reducing the risk of delays and compliance gaps.
Carolina Molecular, which has operated for more than 25 years, provides CAP/CLIA-certified and New York State-registered molecular testing services, including NGS Foundry and bioinformatics analysis. Astoriom specialises in ICH-compliant stability storage, CAP-certified biorepository services, and ultra-low and cryogenic storage solutions across the US, UK and EU.
Trent Carrier, president of Carolina Molecular, said: “By combining our cutting-edge molecular testing with Astoriom’s world-class storage capabilities, we’re streamlining logistics and providing an end-to-end solution at a time when operational efficiency is more critical than ever.”
Astoriom chief executive Lori Ball added: “Our collaboration with Carolina Molecular is a great example of how we can support innovation by working together. Their testing expertise and our biorepository and stability storage capabilities create seamless solutions for customers.”
The alliance comes at a time when demand for integrated service models is growing across life sciences, driven by increasingly complex clinical pipelines and regulatory requirements for sample handling. Analysts have noted that companies are under pressure to accelerate research timelines while maintaining compliance in areas such as genetic testing and long-term sample storage.
Both companies emphasised that the partnership will focus on quality and responsiveness while supporting clients advancing new therapies across multiple therapeutic areas.




